Natco Pharma - Covid-19 Vacuum Weighs On Q2; Future Launches Key: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Natco Pharma Ltd.’s Q2 FY22 revenues de-grew 53% YoY to Rs 377 crore due to sharp decline in export formulations (down 60% YoY to Rs 190 crore) and active pharma ingredients, which declined 62% YoY to Rs 76 crore.
Domestic formulations also posted de-growth of 5% YoY to Rs 103 crore due to likely reduction in sales of Covid-19 portfolio.
Ebitda margins contracted 1576 basis points YoY to 19% and Ebitda declined 74% YoY to Rs 70 crore.
Consequently, Natco Pharma's net profit for the quarter declined 68% YoY to Rs 65 crore. Delta vis-a-vis Ebitda was due to higher other income and lower tax being partially offset by higher depreciation and interest expense. [Note: Base of Q2 FY21 also includes a one-off settlement contribution].
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.